Pharmaceutical - Pharmaceutical, North America, Roche

Filter

1 to 25 of 46 results

ASH 2013: Meeting highlights from Takeda, Roche, Novartis and Gilead

ASH 2013: Meeting highlights from Takeda, Roche, Novartis and Gilead

09-12-2013

The 55th American Society of Hematology (ASH) meeting began in New Orleans on Saturday with a host of…

Gilead SciencesNorth AmericaNovartisPharmaceuticalResearchRocheTakeda Pharmaceuticals

US patient share leaders in first-line BRAF-mutation positive malignant melanoma

27-11-2013

According to US oncologists surveyed in the third quarter of 2013 by BioTrends Research, a unit of Decision…

Bristol-Myers SquibbGlaxoSmithKlineMarkets & MarketingMekinistNorth AmericaOncologyPharmaceuticalRocheTafinlarYervoyZelboraf

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Genentech’s SC Actemra approved by US FDA for severe RA

Genentech’s SC Actemra approved by US FDA for severe RA

22-10-2013

Genentech has announced that the US Food and Drug Administration has approved a subcutaneous formulation…

ActemraAnti-Arthritics/RheumaticsGenentechNorth AmericaPharmaceuticalRegulationRoche

US nephrologists views on prescribing Roche’s Mircera

02-10-2013

Among surveyed US nephrologists, familiarity with Swiss drug major Roche's Mircera is low, but is still…

InjectaferKeryx BiopharmaceuticalsMirceraNeurologicalNorth AmericaPharmaceuticalRocheZerenex

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

FDA advisory panel backs new indication for Genentech's Perjeta

13-09-2013

The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

Roche/Chugai's bitopertin set to garner $1.5 billion sales in 2022

23-08-2013

Swiss drug major Roche (ROG: SIX) and its majority-owned Japanese affiliate Chugai's glycine transporter-1…

AbilifyAbilify MaintenabitopertinChugai PharmaceuticalEuropeGenericsJanssenLundbeckMarkets & MarketingNeurologicalNorth AmericaOtsukaPaliperidonePharmaceuticalRocheSeroquelZyprexa

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Strong uptake of Regeneron/Bayer wet AMD drug Eylea in USA, but Avastin still leads

11-07-2013

The majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal…

AllerganAvastinBayerBiotechnologyEyleaFovistaLucentisMarkets & MarketingNorth AmericaOphthalmicsOphthotechPharmaceuticalRegeneronRoche

Oncologists positive on Tafinlar, Mekinist and nivolumab for unresectable malignant melanoma

11-07-2013

US and European oncologists surveyed by health care advisory firm Decision Resources indicate that overall…

BiotechnologyBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingMekinistnivolumabNorth AmericaOncologyPharmaceuticalRocheTafinlarZelboraf

US FDA backs news indications for Latuda; grants Priority Review for Perjeta

02-07-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Oncologists favor Avastin as first-line therapy for metastatic colorectal cancer

27-06-2013

For the treatment of metastatic colorectal cancer (mCRC), a majority of surveyed US oncologists surveyed…

AvastinBayerBiotechnologyBristol-Myers SquibbErbituxMarkets & MarketingMerck SeronoNorth AmericaOncologyPharmaceuticalRegeneronRocheSanofiStivargaZaltrap

Therapy's induction of remission an attribute that most influences Rxing decisions in rheumatoid arthritis

20-06-2013

The majority of US and European rheumatologists surveyed by health care advisory firm Decision Resources…

AbbVieActemraAnti-Arthritics/RheumaticsEisaiEuropeHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalRocheTakeda PharmaceuticalsXeljanz

Emerging targeted therapies offer advantages over currently-used platinum-resistant ovarian cancer drugs

11-06-2013

The effect of an emerging therapy on key efficacy endpoints, including time to disease progression and…

AmgenAstraZenecaAvastinBiotechnologyMarkets & MarketingMerck & CoNorth AmericaolaparibOncologyPharmaceuticalRochetrebananibvintafolide

Avastin remains preferred DME therapy, despite Lucentis extended label in USA

30-05-2013

Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

US FDA approves companion diagnostic for Tarceva, and new indication for the Roche drug

15-05-2013

The US Food and Drug Administration late yesterday (May 14) approved Swiss drug major Roche (ROG: SIX)…

Boehringer IngelheimNorth AmericaOncologyPharmaceuticalQiagenRegulationRocheTarcevaTomtovok

Regulatory updates on GSK's albiglutide, Roche's hep C test, Activartis AV0113

07-03-2013

UK pharma giant GlaxoSmithKline plc (LSE: GSK) says it has submitted a Marketing Authorization Application…

ActivartisalbiglutideAnti-viralsAV0113BiotechnologyDiabetesEperzanEuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRoche

US FDA approves Roche's late-stage breast cancer drug Kadcyla

25-02-2013

The US Food and Drug Administration on Friday approved Kadcyla (ado-trastuzumab emtansine), a new therapy…

BiotechnologyGenentechImmunoGenKadcylaNorth AmericaOncologyPharmaceuticalRegulationRochetrastuzumab emtansine

Treatment landscape for thyroid carcinoma will change dramatically through 2021; report

05-02-2013

Through 2021, the treatment landscape for thyroid carcinoma will change dramatically in the USA and Europe…

BayerdabrafenibEisaiEuropeGlaxoSmithKlinelenvatinibMarkets & MarketingNexavarNorth AmericaOncologyOXiGENEPharmaceuticalRochetrametinibZelborafZybrestat

FDA clears new use for Roche's Avastin and Novartis' Exjade

25-01-2013

The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

First interferon-free regimens for hepatitis C virus expected to launch in 2014 in the USA and Europe

20-12-2012

For the treatment of hepatitis C virus (HCV), the elimination of interferons (IFNs) from regimens is…

Anti-viralsBiotechnologyEuropeIncivekIncivoJohnson & JohnsonMarkets & MarketingMitsubishi TanabeNorth AmericaPharmaceuticalRocheTelavicVertexVictrelis

FDA Approves Abraxane for NSCLC and expands indication for Actemra

15-10-2012

The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

US oncologists' perceptions of Roche's Perjeta very promising

07-09-2012

Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

1 to 25 of 46 results

Parexel

Parexel

Back to top